Justin Bucci1, Xiaoyang Chen1, Michael LaValley1, Michael Nevitt2, James Torner3, Cora E Lewis4, David T Felson1,5. 1. Boston University, Boston, Massachusetts. 2. University of California at San Francisco. 3. University of Iowa, Iowa City. 4. University of Alabama at Birmingham. 5. University of Manchester and the NIHR Manchester Musculoskeletal Biomedical Research Centre, and Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Abstract
OBJECTIVE: To determine whether intraarticular glucocorticoid (GC) injections are associated with increased knee osteoarthritis (OA) progression compared to hyaluronic acid (HA) injections, which have been reported to delay OA progression and knee replacement. METHODS: We identified participants from 2 large cohort studies, the Osteoarthritis Initiative (OAI) and the Multicenter Osteoarthritis Study. Study visits were performed at regular intervals and included questionnaires about intraarticular GC or HA injection use in the previous 6 months and incident total knee replacement (TKR). Knee radiographs were obtained at each study visit and interpreted in a similar manner. Outcome measures were radiographic progression based on Kellgren/Lawrence (K/L) grade and joint space narrowing (JSN) for both cohorts and based on medial joint space width for OAI participants, and incident TKR. We compared preinjection and postinjection radiographs to generate rate ratios of progression comparing GC injection with HA injection. A Cox proportional hazards model was used to estimate the rate of TKR for both groups. RESULTS: We studied 791 participants (980 knees) with knee OA, of whom 629 reported GC injection use and 162 HA injection use. Rate ratios of progression were similar between those receiving GCs and those receiving HA for JSN (1.00 [95% confidence interval (95% CI) 0.83-1.21]), K/L grade (1.03 [95% CI 0.83-1.29]), and medial joint space width (1.03 [95% CI 0.72-1.48]). Hazard of TKR was slightly lower for those receiving intraarticular GC compared to those receiving HA (hazard ratio 0.75 [95% CI 0.51-1.09]). CONCLUSION: Intraarticular GC injections are not associated with an increased risk of knee OA progression compared to HA.
OBJECTIVE: To determine whether intraarticular glucocorticoid (GC) injections are associated with increased knee osteoarthritis (OA) progression compared to hyaluronic acid (HA) injections, which have been reported to delay OA progression and knee replacement. METHODS: We identified participants from 2 large cohort studies, the Osteoarthritis Initiative (OAI) and the Multicenter Osteoarthritis Study. Study visits were performed at regular intervals and included questionnaires about intraarticular GC or HA injection use in the previous 6 months and incident total knee replacement (TKR). Knee radiographs were obtained at each study visit and interpreted in a similar manner. Outcome measures were radiographic progression based on Kellgren/Lawrence (K/L) grade and joint space narrowing (JSN) for both cohorts and based on medial joint space width for OAI participants, and incident TKR. We compared preinjection and postinjection radiographs to generate rate ratios of progression comparing GC injection with HA injection. A Cox proportional hazards model was used to estimate the rate of TKR for both groups. RESULTS: We studied 791 participants (980 knees) with knee OA, of whom 629 reported GC injection use and 162 HA injection use. Rate ratios of progression were similar between those receiving GCs and those receiving HA for JSN (1.00 [95% confidence interval (95% CI) 0.83-1.21]), K/L grade (1.03 [95% CI 0.83-1.29]), and medial joint space width (1.03 [95% CI 0.72-1.48]). Hazard of TKR was slightly lower for those receiving intraarticular GC compared to those receiving HA (hazard ratio 0.75 [95% CI 0.51-1.09]). CONCLUSION: Intraarticular GC injections are not associated with an increased risk of knee OA progression compared to HA.
Authors: Ian J Wallace; Steven Worthington; David T Felson; Robert D Jurmain; Kimberly T Wren; Heli Maijanen; Robert J Woods; Daniel E Lieberman Journal: Proc Natl Acad Sci U S A Date: 2017-08-14 Impact factor: 11.205
Authors: A Cranney; P Tugwell; S Cummings; P Sambrook; J Adachi; A J Silman; W J Gillespie; D T Felson; B Shea; G Wells Journal: J Rheumatol Date: 1997-06 Impact factor: 4.666
Authors: Anand R Shewale; C Lowry Barnes; Lori A Fischbach; Songthip T Ounpraseuth; Jacob T Painter; Bradley C Martin Journal: J Arthroplasty Date: 2017-07-14 Impact factor: 4.757
Authors: G Neumann; D Hunter; M Nevitt; L B Chibnik; K Kwoh; H Chen; T Harris; S Satterfield; J Duryea Journal: Osteoarthritis Cartilage Date: 2008-11-12 Impact factor: 6.576
Authors: C Zeng; N E Lane; D J Hunter; J Wei; H K Choi; T E McAlindon; H Li; N Lu; G Lei; Y Zhang Journal: Osteoarthritis Cartilage Date: 2019-01-29 Impact factor: 6.576
Authors: Yilun Wang; Uyen-Sa D T Nguyen; Nancy E Lane; Na Lu; Jie Wei; Guanghua Lei; Chao Zeng; Yuqing Zhang Journal: Arthritis Care Res (Hoboken) Date: 2021-03-13 Impact factor: 4.794
Authors: Timothy E McAlindon; Michael P LaValley; William F Harvey; Lori Lyn Price; Jeffrey B Driban; Ming Zhang; Robert J Ward Journal: JAMA Date: 2017-05-16 Impact factor: 56.272